Linked Life Data

11802608

Source:http://linkedlifedata.com/resource/pubmed/id/11802608

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2002-1-22
pubmed:abstractText
Hepatitis B and C viruses are the etiologic agents of most cases of the world's most common cancer: hepatocellular carcinoma (HCC). The incidence of this cancer is rising globally, due largely to the epidemic spread of HCV infection. It is thus essential that means be found to prevent this lethal disease by prophylactic and therapeutic immunization. DNA-based immunization has the ability to induce both cell-mediated and humoral immunity, and thus lends itself to therapeutic immunization strategies. DNA-based immunization also lends itself to the design of multivalent immunogens targeted at various pathogens. This strategy will facilitate economical immunization in the developing world. DNA-based immunization has protected chimpanzees against HBV challenge and, in combination with recombinant canarypox boosters, has downregulated chronic HBV infection in a chimpanzee. DNA-based immunization is still in its infancy for HCV infections. Substantial immunogenicity has been demonstrated, particularly in mice; however, enhancement of immunogenicity will be required to achieve prophylactic or therapeutic efficacy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1246-7820
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
467-70
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Perspectives on prophylactic and therapeutic immunization against hepatitis B and C viruses.
pubmed:affiliation
Laboratory of Virology, Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th St, New York, N.Y. 10021, USA. aprince@nybc.org
pubmed:publicationType
Journal Article, Review